Mobility, in case you haven’t heard, is the up-and-coming tech buzzword driving the future of transportation. As defined by the auto industry, mobility refers to moving goods and people from point A to point B. This encompasses vehicles for personal... Read more »
The race to develop a gene therapy for hemophilia just moved another few feet forward. Spark Therapeutics, which is one of several companies developing a treatment, is the latest to provide its first glimpse of clinical data in human patients.
As... Read more »
We’re a little over a month away from our fifth annual Bay Area robotics conference. This year’s Robo Madness West has a new spin: it’s happening as part of the 2016 Sensors Expo & Conference at the McEnery Convention Center in... Read more »
“The consumption of data by humans has increased maybe millions of times compared to what we used to use,” Ajeet Singh says. “This is possible because of search.”
By that, serial entrepreneur Singh means search engines like Google and Microsoft’s Bing,... Read more »
[Editor’s note: This is part of a series of stories examining entrepreneurship on MIT’s campus and beyond.]
In 1901, 40 years after the Massachusetts Institute of Technology was founded, alumnus and inventor William Nickerson co-founded the company that would... Read more »
Elemental Technologies and Blue Box Group were acquired by Amazon and IBM, respectively, in two of the Northwest’s most prominent technology deals of 2015. Both received initial venture capital investments from Voyager Capital.
With these successful exits behind them and... Read more »
South San Francisco, CA-based Genentech, a division of international health giant Roche, announced today the U.S. approval of its drug atezolizumab (Tecentriq) for the most common form of bladder cancer.
Nearly 77,000 new cases of the cancer, called urothelial carcinoma, will... Read more »
The gene editing system known as CRISPR-Cas9 has electrified the world of science and led to a slew of startups, including two—Editas Medicine and Intellia Therapeutics—that have already gone public. The latest to join the fray is Agenovir, a company... Read more »
[Updated, 1:15 pm ET and 7:53pm ET, see below] Cambridge, MA-based Foundation Medicine (NASDAQ: FMI), which analyzes tumor and blood samples from cancer patients and provides suggestions for potential genetically targeted medicines, is suing rival diagnostic firm Guardant... Read more »